These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33497525)

  • 21. Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives.
    Gori M; D'Elia E; Senni M
    Int J Cardiol; 2019 Apr; 281():158-165. PubMed ID: 30420146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and Pharmacodynamics of Sacubitril/Valsartan in Maintenance Hemodialysis Patients with Heart Failure.
    Feng Z; Wang X; Zhang L; Apaer R; Xu L; Ma J; Li X; Che H; Tang B; Xiong Y; Xia Y; Xiao J; Su X; Wang Y; Dou X; Chen J; Mei L; Xue Z; Kong Y; Li S; Zhang H; Lin T; Wen F; Fu X; Tao Y; Fu L; Li Z; Huang R; Ye Z; He C; Shi W; Liang X; Ke G; Liu S
    Blood Purif; 2022; 51(3):270-279. PubMed ID: 34753147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect.
    Tashiro K; Kuwano T; Ideishi A; Morita H; Idemoto Y; Goto M; Suematsu Y; Miura SI
    Cardiol Res; 2020 Dec; 11(6):376-385. PubMed ID: 33224383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacubitril/valsartan decreases mortality in the rat model of the isoprenaline-induced takotsubo-like syndrome.
    Ali A; Redfors B; Alkhoury J; Oras J; Henricsson M; Boren J; Björnson E; Espinosa A; Levin M; Gan LM; Omerovic E
    ESC Heart Fail; 2021 Oct; 8(5):4130-4138. PubMed ID: 34463049
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.
    Li X; Zhu Q; Wang Q; Zhang Q; Zheng Y; Wang L; Jin Q
    Cardiovasc Drugs Ther; 2020 Oct; 34(5):629-640. PubMed ID: 32444995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction.
    Mohebi R; Liu Y; Piña IL; Prescott MF; Butler J; Felker GM; Ward JH; Solomon SD; Januzzi JL
    J Am Coll Cardiol; 2022 Oct; 80(16):1529-1541. PubMed ID: 36229089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential Effects of Sacubitril/Valsartan on Diastolic Function in Mice With Obesity-Related Metabolic Heart Disease.
    Croteau D; Qin F; Chambers JM; Kallick E; Luptak I; Panagia M; Pimentel DR; Siwik DA; Colucci WS
    JACC Basic Transl Sci; 2020 Sep; 5(9):916-927. PubMed ID: 33015414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin Receptor-Neprilysin Inhibition Attenuates Right Ventricular Remodeling in Pulmonary Hypertension.
    Sharifi Kia D; Benza E; Bachman TN; Tushak C; Kim K; Simon MA
    J Am Heart Assoc; 2020 Jul; 9(13):e015708. PubMed ID: 32552157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Left Ventricular Ejection Fraction Change Following Treatment With Sacubitril/Valsartan.
    Mohebi R; Liu Y; Felker GM; Prescott MF; Piña IL; Butler J; Ward JH; Solomon SD; Januzzi JL
    JACC Heart Fail; 2023 Jan; 11(1):44-54. PubMed ID: 36599549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protective Effects of Sacubitril/Valsartan on Cardiac Fibrosis and Function in Rats With Experimental Myocardial Infarction Involves Inhibition of Collagen Synthesis by Myocardial Fibroblasts Through Downregulating TGF-β1/Smads Pathway.
    Wu M; Guo Y; Wu Y; Xu K; Lin L
    Front Pharmacol; 2021; 12():696472. PubMed ID: 34135764
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction.
    Tran JS; Havakuk O; McLeod JM; Hwang J; Kwong HY; Shavelle D; Zile MR; Elkayam U; Fong MW; Grazette LP
    ESC Heart Fail; 2021 Apr; 8(2):1706-1710. PubMed ID: 33522140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction Between Sacubitril and Valsartan in Preventing Heart Failure Induced by Aortic Valve Insufficiency in Rats.
    Maslov MY; Foianini S; Mayer D; Orlov MV; Lovich MA
    J Card Fail; 2019 Nov; 25(11):921-931. PubMed ID: 31539619
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
    Zhang Y; Yuan M; Suo Y; Yang Q; Shao S; Li Y; Wang Y; Bao Q; Liu T; Li G
    Clin Exp Pharmacol Physiol; 2022 Aug; 49(8):848-857. PubMed ID: 35596518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
    Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
    J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.
    Albert NM; Swindle JP; Buysman EK; Chang C
    J Am Heart Assoc; 2019 May; 8(9):e011089. PubMed ID: 31023122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
    Selvaraj S; Claggett BL; Pfeffer MA; Desai AS; Mc Causland FR; McGrath MM; Anand IS; van Veldhuisen DJ; Kober L; Janssens S; Cleland JGF; Pieske B; Rouleau JL; Zile MR; Shi VC; Lefkowitz MP; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2020 Nov; 22(11):2093-2101. PubMed ID: 32840930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Introduction of sacubitril/valsartan in primary care follow-up of heart failure: a prospective observational study (THESEUS).
    Dieterle T; Schaefer S; Meyer I; Ackermann G; Ahmed K; Hullin R
    ESC Heart Fail; 2020 Aug; 7(4):1626-1634. PubMed ID: 32369265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats.
    Raj P; Sayfee K; Parikh M; Yu L; Wigle J; Netticadan T; Zieroth S
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.